Kazia Therapeutics Unveils First-in-Class Nuclear PD-L1 Degrader NDL2 Targeting Immunotherapy Resistance
核心洞察
Kazia Therapeutics (搜索) announced compelling preclinical data for NDL2 (搜索), a potentially first-in-class protein degrader targeting nuclear PD-L1 (搜索), a previously unrecognized driver of immunotherapy resistance and metastatic progression.
In murine triple-negative breast cancer (搜索) models, NDL2 (搜索) reduced primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1 (搜索) therapy, with 50% reduction in lung metastases.
Nuclear PD-L1 (搜索) was identified as a transcriptionally active regulator promoting epithelial-to-mesenchymal transition, cancer stem-like phenotypes, and immune exhaustion not addressed by current PD-1 (搜索)/PD-L1 antibodies.
Kazia Therapeutics (搜索) has announced compelling preclinical and translational data supporting the development of NDL2 (搜索), a potentially first-in-class protein degrader designed to selectively eliminate nuclear PD-L1 (搜索). The data, generated by Professor Sudha Rao and her team at QIMR Berghofer (搜索), identify nuclear PD-L1 as a previously unaddressed intracellular driver of immunotherapy resistance and metastatic progression that is not targeted by currently approved PD-1 (搜索)/PD-L1 antibodies.
Novel Mechanism Addresses Immunotherapy Resistance
Unlike conventional PD-1 (搜索)/PD-L1 (搜索) antibodies that block extracellular signaling, NDL2 (搜索) targets nuclear PD-L1 proteins linked to aggressive and therapeutically resistant mesenchymal and stem-like cancer phenotypes. Kazia's collaborators identified nuclear PD-L1 as a transcriptionally active regulator that promotes epithelial-to-mesenchymal transition (EMT), cancer stem-like phenotypes, metastatic dissemination, and immune exhaustion and evasion.
Nuclear PD-L1 (搜索) was shown to be enriched in immunotherapy-resistant tumor cells, metastatic lesions, and circulating tumor cells, regulating gene programs associated with invasion, survival, and immune suppression. This intracellular PD-L1 pool represents a previously inaccessible resistance mechanism not addressed by existing therapies.
Robust Preclinical Efficacy Data
In murine triple-negative breast cancer (搜索) (TNBC) preclinical models, NDL2 (搜索) demonstrated significant anti-tumor activity, reducing primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1 (搜索) therapy. The combination treatment also achieved a 50% reduction in lung metastases, addressing one of the most significant limitations of current immunotherapies.
Spatial transcriptomic and proteomic profiling revealed that NDL2 (搜索) treatment drove a coordinated shift toward a less aggressive tumor state and a more active anti-tumor immune response. Specific effects included suppressed aggressive mesenchymal phenotype and metastasis-associated gene programs (including VIM, ZEB1, FN1), reduced oncogenic PI3K (搜索)/AKT (搜索) and MAPK signaling, increased intratumoral CD8+ cytotoxic T-cell infiltration and Granzyme B expression, and reduced markers of T-cell exhaustion, including TIM-3 and LAG-3.
Translational Evidence and Biomarker Potential
Using an advanced epigenetic digital pathology and liquid biopsy platform, researchers demonstrated that nuclear PD-L1 (搜索) is selectively enriched in resistant and metastatic tumors, including TNBC, melanoma (搜索), non-small cell lung cancer (搜索) (NSCLC), and colorectal cancer (搜索). Distinct nuclear versus cytoplasmic PD-L1 post-translational modification states can be reliably quantified in circulating tumor cells.
Longitudinal liquid biopsy analysis showed that reductions in nuclear PD-L1 (搜索) preceded radiographic tumor responses, supporting its potential utility as an early predictive biomarker of treatment benefit. These findings support a precision-guided development strategy, integrating therapy and diagnostics from the outset.
Favorable Safety Profile and Development Strategy
NDL2 (搜索) demonstrated a favorable preclinical safety and pharmacokinetics profile with no observed toxicity, no hemolysis, preserved immune checkpoint function at the cell surface, and favorable plasma stability. As a bicyclic peptide-based degrader, NDL2 combines the selectivity of biologics with the tissue penetration, manufacturability, and pharmacokinetic advantages of small molecules.
Initial clinical development is expected to prioritize immunotherapy-refractory solid tumors where PD-L1 (搜索) biology, metastatic progression, and resistance to immune checkpoint inhibitors are well established. Based on the underlying mechanism and preclinical data, these may include triple-negative breast cancer (搜索) and melanoma (搜索), with potential expansion into larger PD-1 (搜索)/PD-L1-treated populations such as lung and colorectal cancers.
Clinical Timeline and Strategic Positioning
Kazia and its collaborators are advancing IND-enabling studies, with the objective of initiating first-in-human clinical trials in 2027, subject to regulatory review. The company plans to present elements of this dataset at an upcoming oncology-focused scientific meeting in the second quarter of 2026.
"The pharmaceutical industry is clearly signaling that targeted protein degradation represents a transformational opportunity in oncology," said Dr. John Friend, Chief Executive Officer of Kazia Therapeutics (搜索). "What differentiates NDL2 (搜索) is that we are applying protein degradation to PD-L1 (搜索) as one of the most clinically validated targets in cancer, while addressing a resistance mechanism not reached by existing therapies."
The program uniquely combines an innovative approach with one of the most clinically validated targets in oncology, as PD-L1 (搜索) underpins multiple FDA-approved therapies across numerous tumor types and indications globally. By selectively degrading the nuclear, resistance-associated form of PD-L1, Kazia's approach applies a novel and differentiated mechanism to a well-established biological pathway.